Efficacy
of PARPi monotherapy and the impact to subsequent platinum-based
chemotherapy in BRCA1/2 -mutated ovarian cancer patients with
secondary platinum-sensitive relapse
Yana Ma12*, Ning Li3*, Hualei
Bu12*, Yongwen Huang4, Chengjuan
Jin5, Hao Wen6, Shuai
Feng7, Hui Zhang8, Beihua
Kong12,
Lingying
Wu3#, Kun Song12#
*
Contributed equally
1 Department of Obstetrics and Gynecology, Qilu
Hospital of Shandong University, Jinan,
250012,
China
2 Division of Gynecology oncology, Qilu Hospital of
Shandong University, Jinan, 250012, China
3 Department of Gynecologic Oncology, National Cancer
Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing, 100021, China.
4 Gynecologic Department, Sun Yat-sen University
Cancer Center, Guangzhou, 510060, China
5 Department of Obstetrics and Gynecology, Shanghai
General Hospital, School of Medicine, Shanghai Jiao Tong University,
Shanghai, 201620, China
6 Department of Gynecologic Oncology, Fudan University
Shanghai Cancer Center, Shanghai, 201620, China.
7 Gynecological Oncology Department, Shandong Cancer
Hospital and Institute, Shandong First Medical University and Shandong
Academy of Medical Sciences, Jinan, 250012, China
8 Department of Gynecology, The Fourth Hospital of
Hebei Medical University, Shijiazhuang, 050000, China.